ScoreWhy is United Therapeutics Corp. ?
1
High Management Efficiency with a high ROE of 16.12%
2
The company is Net-Debt Free
3
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 16.12%
4
Flat results in Mar 26
- RAW MATERIAL COST(Y) Grown by 6.22% (YoY)
- DEBT-EQUITY RATIO (HY) Highest at -36.5 %
- NET SALES(Q) Lowest at USD 781.5 MM
5
With ROE of 18.50%, it has a attractive valuation with a 5.19 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 67.18%, its profits have risen by 9.9% ; the PEG ratio of the company is 2
6
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating performance in long term as well as near term
- Along with generating 67.18% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to United Therapeutics Corp. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is United Therapeutics Corp. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
United Therapeutics Corp.
67.18%
2.07
47.20%
S&P 500
22.99%
1.78
12.93%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
16.50%
EBIT Growth (5y)
20.62%
EBIT to Interest (avg)
31.53
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.42
Tax Ratio
22.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
32.42%
ROE (avg)
16.12%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
5.19
EV to EBIT
22.37
EV to EBITDA
21.18
EV to Capital Employed
8.12
EV to Sales
10.65
PEG Ratio
2.02
Dividend Yield
NA
ROCE (Latest)
36.30%
ROE (Latest)
18.50%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 1,563.3 MM
ROCE(HY)
Highest at 20.26%
-13What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 6.22% (YoY
DEBT-EQUITY RATIO
(HY)
Highest at -36.5 %
NET SALES(Q)
Lowest at USD 781.5 MM
OPERATING PROFIT(Q)
Lowest at USD 348.4 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 44.58 %
PRE-TAX PROFIT(Q)
Lowest at USD 256.7 MM
NET PROFIT(Q)
Lowest at USD 221.7 MM
EPS(Q)
Lowest at USD 5.82
Here's what is working for United Therapeutics Corp.
Operating Cash Flow
Highest at USD 1,563.3 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Here's what is not working for United Therapeutics Corp.
Pre-Tax Profit
At USD 256.7 MM has Fallen at -39.2%
over average net sales of the previous four periods of USD 422.23 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD 221.7 MM has Fallen at -32.45%
over average net sales of the previous four periods of USD 328.2 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Net Sales
Lowest at USD 781.5 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (USD MM)
Operating Profit
Lowest at USD 348.4 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Operating Profit Margin
Lowest at 44.58 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Pre-Tax Profit
Lowest at USD 256.7 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD 221.7 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
EPS
Lowest at USD 5.82
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Highest at -36.5 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 6.22% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
